Moderna Adds Bearish Views Ahead of Cancer Vaccine Data (MRNA)

Moderna adds bearish views ahead of cancer vaccine data (MRNA)

Moderna (MRNA) stock rallies despite bearish views from analysts ahead of new late-stage trial data for Merck (MRK)-partnered melanoma cancer vaccine. Read more here.

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers you need to see first.

Moderna Shares Rise 4.5% Ahead of Melanoma Trial Results

The Phase 3 INTerpath-001 findings are scheduled for presentation Oct. 24 in Madrid. The companies disclosed no numerical efficacy results in August.

A Personalized Cancer Vaccine Just Passed Phase 3

A cancer vaccine tailored to a patient’s tumor just hit its targets in a Phase 3 melanoma trial paired with Keytruda, after surgery. Promising? Yes. A universal cancer vaccine? Not ye 🔗 Watch the full video: https://youtu.be/Z9BJb8lS1lo Credit to : Longevity Science News